Journal article
Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update
American journal of hematology, Vol.97(1), pp.99-118
01 Jan 2022
PMID: 34661922
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Patients with multiple myeloma who are refractory to currently available effective therapies have short expected survival. Modalities harvesting the knowledge of the immune characteristics and microenvironment of myeloma such as chimeric antigen receptor (CAR) T‐lymphocytes, bispecific antibodies (bsAbs), and antibody‐drug conjugates (ADCs) have shown potential in early phase trials. Based on data from phase 2 studies, idecabtagene vicleucel (ide cel), an anti‐B‐cell maturation antigen CAR T‐product and belantamab mafodotin (belamaf), an ADC are currently approved in the relapsed/refractory setting. bsAbs have shown promise with quick and deep responses. In this review, we summarize the available evidence on these treatments from clinical trials.
Metrics
2 Record Views
Details
- Title
- Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update
- Creators
- Arjun Lakshman - University of Pittsburgh Medical CenterShaji K. Kumar - Mayo Clinic
- Publication Details
- American journal of hematology, Vol.97(1), pp.99-118
- Publisher
- John Wiley & Sons, Inc
- Number of pages
- 20
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000716574900001
- Scopus ID
- 2-s2.0-85118831187
- Other Identifier
- 991022059810704721
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Hematology